Navigation Links
Europe to tackle brain disorder research by linking industry, academia
Date:11/27/2007

Attempts to cure brain-related disorders have proved less successful than therapies for other major conditions such as heart cancer, even though just as many people suffer from them. About 600 million worldwide each year are afflicted by depression alone, more than any other condition except heart disease, and yet of those given existing drugs, only half recover.

Furthermore progress treating depression as well as other major brain disorders has stalled. This stark fact lies behind an ambitious European proposal to revive the field. The proposal, to be presented at EuroBioForum, in Lisbon in December 2007, aims to develop a ground breaking multi-disciplinary research project which would propel Europe to the head of global research into the crucial role of neurotransmitters in brain disorders. Bringing together the relevant specialisms in chemistry, radio-chemistry, in vivo modelling, and above all PET and SPECT scanning, the project would exploit recent advances both in PET (Positron Emission Tomography), and SPECT (Single Photon Emission Computer Tomography), enabling metabolic activity such as levels of neurotransmitters to be determined with greater accuracy in space and quantity.

The objective is to develop new methods to identify the release of neurotransmitters such as noradrenaline, serotonin, acetylcholine, and endorphins, in the brain and so examine their role in major brain disorders. This in turn will enable more effective therapies to be developed than current drugs, which often fail to work, according to the projects leader David Nutt, Professor of Psychopharmacology at the University of Bristol, UK. Professor Nutt is presenting his vision for this groundbreaking project at the EuroBioForum conference, which is organised by the European Science Foundation (ESF) with support from the European Commission.

The programme has great potential for human health given the vast number of people affected, but as Professor Nutt pointed out, the scale of the task is great.

We dont even know for example whether serotonin levels are high or low in depressed people, said Professor Nutt. This is despite the fact that many current anti-depressant drugs, including Prozac, alter the uptake of serotonin by key receptors in the brain. Professor Nutts observation shows that there is a lack of knowledge over how existing drugs work, and until greater understanding is reached, it will be very difficult to make further progress.

Until now researchers have been deterred by the sheer extent of the problem in unravelling the complex links between multiple neurotransmitters and a range of conditions. This, said Professor Nutt, is big science on the same level as the Human Genome Project, or splitting the atom. It requires a huge harmonised effort, combining the forces of academia and the pharmaceutical industry. Until now neurological research has tended to be fragmented, with industry more concerned with improving existing therapies and determining correct combinations of drugs and dosage levels. Meanwhile academia has tended to plough too many small furrows, without tackling the big picture.

The EuroBioForum conference will provide the platform for researchers to unite behind a common larger goal. As Professor Nutt commented, the conference offers a unique opportunity for the academic community, research funding organisations, government, industry and policy making organisations to share ideas and contribute to key policy and funding decisions. He added, Im extremely pleased to have been invited to such an important event and delighted that for the first time a brain research programme has been shortlisted under this initiative.


'/>"/>

Contact: Dr. Fiona Kernan
fkernan@esf.org
33-388-762-180
European Science Foundation
Source:Eurekalert

Related medicine news :

1. Eligard(R) six-month formulation successfully completes European approval procedure
2. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
3. Medical Services International Inc. Completes Testing for European Union (EU) Application
4. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
5. Europe-wide Researchers Night
6. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
7. Launch of second European Cancer Research Funding survey
8. Cancer control in Europe works; now it is time to extend it to poorer countries
9. Political decisions harming cancer treatment in Europe
10. European directive will halt use of MRI scans; cancer diagnosis and treatment will suffer
11. Stille and Enova Form Strategic Partnership to Introduce Worlds Brightest LED Cordless Surgical Headlights Into Europe and Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in global law ... 21st Drug & Medical Device Litigation Conference , taking place in New York Dec. ... chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and the Trial ...
(Date:12/2/2016)... ... , ... Advanced Inc., a leading provider of travel therapy and travel nursing ... as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served as ... operational leadership experience to Advanced Inc. He began his career in finance at Ernst ...
(Date:12/2/2016)... ... ... With the number of pain management programs available for people suffering with constant ... works for them. When an inventor from Suisun City, Calif., was unsuccessful in finding ... it with others. , He developed a prototype for PRO GO MASSAGE to relieve ...
(Date:12/2/2016)... ... December 02, 2016 , ... CloudLIMS.com, a ... SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and testing laboratories ... and disposal. The new version is a faster and a more efficient product, ...
(Date:12/2/2016)... ... 02, 2016 , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, ... into Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started in ... the details line up exactly with Bible Prophecy – a protected way for those ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , December 2, 2016 On ... Committee honored excellence in research, development and innovation in ... gala dinner was held in the presence of Sergey ... Russian Federation , Natalia Sanina, First ... Mikhail Murashko , Head of Roszdravnadzor, National Service of ...
(Date:12/2/2016)... CVS Health Corporation (NYSE: CVS ... City on Thursday, December 15, 2016, beginning at 8:00 a.m. (ET). Senior ... an in-depth review of the company,s strategies to drive ... also discuss 2017 earnings guidance during the event. ... will be broadcast simultaneously on the Investor Relations portion ...
(Date:12/2/2016)... -- On Thursday, the NASDAQ Composite and the ... Dow Jones Industrial Average managed to stay in green. Losses ... prompted Stock-callers this morning to look at the performances of ... ), Smith & Nephew PLC (NYSE: SNN ), ... Therapeutics Inc. (NASDAQ: KOOL ). You can access ...
Breaking Medicine Technology: